Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.620
+0.050 (3.18%)
Oct 28, 2026, 4:00 PM EDT - Market closed
Inhibikase Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Inhibikase Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $5.55. The average 1-year stock price forecast is 242.59% higher than the current stock price, while the lowest is $1.50 (-7.41%) and the highest is $8.00 (+393.83%).
Price Target: $5.55 (+242.59%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Inhibikase Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 8 | 8 | 8 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 9 | 9 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Hold Initiates $1.5 | Hold | Initiates | $1.5 | -7.41% | Oct 13, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $5 | Buy | Maintains | $5 | +208.64% | Sep 15, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $8 | Buy | Maintains | $8 | +393.83% | Aug 14, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $5 | Buy | Maintains | $5 | +208.64% | Aug 12, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $8 | Buy | Reiterates | $8 | +393.83% | Jul 31, 2026 |
Financial Forecast
Revenue This Year
187.50K
Revenue Next Year
250.00K
from 187.50K
Increased by 33.33%
EPS This Year
-0.40
EPS Next Year
-0.42
from -0.40
EPS and Forward PE are based on non-GAAP adjusted numbers.